INTENSIVE CARE MEDICINE重症监护医学
INTENSIVE CARE MEDICINE(英文缩写 INTENS CARE MED),ISSN 0342-4642,eISSN 1432-1238,中文译名:重症监护医学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 41.787 | Q1 |
| 2022 | 38.900 | Q1 |
| 2023 | 27.100 | Q1 |
| 2024 | 21.200 | Q1 |
| 2025 | 22.000 | Q1 |
INTENSIVE CARE MEDICINE 最新收录文献
-
3. Beyond classical boundaries: rethinking ICU access in acute leukemia.
3. 超越传统界限：重新思考急性白血病中的ICU准入PMID:日期:2026-09-22该文献暂无摘要。
-
4. A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery.
4. 一项多中心、随机、双盲、安慰剂对照的2期试验，旨在评估ilofotase alfa在开胸心脏手术后存在肾损伤风险患者中的安全性和有效性PMID:日期:2026-09-21Acute impairment of kidney function after cardiac surgery is common and associated with an increased morbidity and mortality. Ilofotase alfa has demonstrated potential to attenuate renal injury through its immunomodulatory effects. We evaluated the safety and efficacy of ilofotase alfa in preventing renal functional impairment in cardiac surgery patients. This phase 2, multi-center, randomized, double-blinded, placebo-controlled trial employing a two-arm, parallel-group design randomized adult patients at a high risk of renal functional impairment after on-pump cardiac surgery. Patients with a pre-existent estimated glomerular filtration rate of 25-65 ml/min/1.73m scheduled to undergo complex cardiac surgery were eligible. Patients received two intravenous doses (128 mg) of ilofotase alfa or placebo perioperatively. The primary endpoint was the ratio between the highest serum creatinine levels within five days postoperative relative to the pre-operative level (sCrRatio). The secondary endpoint was major adverse kidney events up to day 60 (MAKE60). In total, 244 patients were randomized of whom 204 received two doses and were included in the trial analysis: 109 patients were treated with ilofotase alfa and 95 received placebo. The mean±SD sCrRatio in the ilofotase alfa group was 1.21±0.42, compared to 1.27±0.50 for placebo (p=0.31). MAKE60 incidence was 15.9% in the ilofotase alfa group and 15.4% in the placebo group (p=0.87). No safety concerns were raised. Administration of ilofotase alfa did not attenuate short- and longer-term renal function loss in patients at a high risk of renal functional impairment after on-pump cardiac surgery. No safety concerns of ilofotase alfa emerged. EUCT Number: 2023-505859-45 US IND Number: 117 605 ClinicalTrials.gov ID: NCT06168799.
-
5. Rehabilitation and the post-intensive care syndrome across the recovery continuum: a narrative review.
5. 康复与重症监护后综合征在恢复连续体中的叙述性综述PMID:日期:2026-09-09Improved survival from critical illness has produced a growing population of intensive care unit (ICU) survivors with new or worsened physical, cognitive, and mental-health impairment, defined as post-intensive care syndrome (PICS), and frequent distress among families/caregivers (PICS-family, PICS-F). This narrative review synthesises the evidence in adults treated in high-resource settings. Rather than a formal guideline process, we used a structured descriptive approach: for each recommendation, we identified the predominant study design, assessed the consistency of findings, summarised uncertainties, and assigned an evidence-strength label (high, moderate, low, or insufficient). We summarise the definition of PICS and its overlap with related constructs (post-sepsis morbidity, chronic critical illness, post-COVID conditions, and frailty); the mechanisms linking acute injury to persistent disability, including skeletal-muscle pathobiology, neuroinflammation, mitochondrial and neuroendocrine dysfunction, and epigenetic change; and the instruments assessing the three PICS core domains (recommending a two-step assessment approach), as well as quality of life, across the care continuum. We describe preventive and rehabilitative interventions from the ICU (e.g., the ABCDEF bundle that includes light/no sedation, delirium prevention, early mobilisation and family participation) through the ward to the post-hospital phase, the heterogeneous organisation of post-ICU recovery services, PICS-F, the educational and cultural change needed, and the health-system and policy context. PICS-F affects 20-60% of relatives; nurse-led family interventions seem promising. The evidence base remains limited and heterogeneous, preventing firm recommendations. Research priorities include harmonised outcome measurement, phenotyping of recovery trajectories, the optimal dose and timing of rehabilitation, and rigorous comparison of follow-up models.
-
6. Distinct weaning phenotypes in patients unsuccessful in weaning from invasive mechanical ventilation: a secondary analysis of the WEAN SAFE cohort.
6. 有创机械通气脱机失败患者的不同脱机表型：WEAN SAFE队列的二次分析PMID:日期:2026-09-09To characterise the trajectories and outcomes of patients who enter the weaning process but fail to wean from invasive mechanical ventilation (MV). In this secondary analysis of the WorldwidE AssessmeNt of Separation of pAtients From ventilatory assistancE (WEAN SAFE) cohort, we examined weaning duration and intensity, decisions to withdraw or withhold life-sustaining therapy (WLST), and clinical outcomes in patients not weaning from invasive ventilation. The primary outcome was ICU mortality. Of the 5664 patients in the study population, 1270 (22.4%) never underwent a separation attempt (SA), while 4394 (77.6%) had at least one SA; of these, 664 (15.1%) eventually failed weaning from invasive MV at day 90, while 3730 (65.9%) successfully weaned. Failed-Wean patients had the longest duration of invasive ventilation and longest ICU stay of all groups. Compared with Successful-Wean, Failed-Wean patients underwent more separation attempts, but fewer attempted extubations and more reintubations and tracheostomies. ICU mortality was 78% in Failed-Wean compared with 2% in Successful-Wean. Three clinically distinct Failed-Wean phenotypes were identified, distinguished by separation attempt count and WLST timing: Phenotype A (single SA + WLST), Phenotype B (single SA, no WLST), and Phenotype C (> 1 SA). A failed-first SA was strongly associated with WLST decisions. In this cohort, a WLST decision was associated with a higher hazard of ICU mortality and shorter median time to ICU death. Three weaning failure phenotypes were identified with distinct clinical profiles, weaning trajectories, and outcomes. A strong relationship exists between failed first separation attempts, WLST decision, and the risk of death, which deserves further investigation. ClinicalTrials.gov, NCT03255109.
-
7. Beyond the ventilator: deploying adjuvant therapies across the course of ARDS.
7. 超越呼吸机：在急性呼吸窘迫综合征全程中应用辅助治疗PMID:日期:2026-09-02该文献暂无摘要。
-
8. Surviving Sepsis Campaign beyond survival: aligning sepsis care with patient goals.
8. 超越生存的脓毒症生存运动：将脓毒症护理与患者目标相结合PMID:日期:2026-08-31该文献暂无摘要。
-
9. Sepsis-associated liver injury: from liver-test risk signals to immunobiology-guided precision medicine.
9. 脓毒症相关性肝损伤：从肝脏检测风险信号到免疫生物学指导的精准医学PMID:日期:2026-08-31该文献暂无摘要。
-
10. Hypernatremia in the critically Ill: beyond free water replacement.
PMID:日期:2026-08-31该文献暂无摘要。